Physician leaders and other clinicians from the American Society of Addiction Medicine ASAM converged on Capitol Hill today to call on members of Congress to take bold, swift steps to reverse the course of the addiction and overdose crisis in the US by supporting key legislation that would close the gap in teaching, standardizing and covering addiction medicine.

ASAM joined 47 other organizations in urging Congress to oppose the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019, which would exempt certain tobacco products from FDA regulation

Penny Mills, ASAM’s Executive Vice President (EVP) and CEO, has decided she will retire at the beginning of June 2020.

ASAM endorses the American College of Medical Toxicology's position statement "Buprenorphine Administration in the Emergency Department."

ASAM sent a letter urging members of Congress to support the Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act), which would place significant restrictions upon flavored tobacco products.

ASAM and members of the Coalition to Stop Opioid Overdose submitted a letter in support of H.R. 3925, the Reducing Barriers to Substance Use Treatment Act.

ASAM submitted a comment letter to the Department of Health and Human Services’ Assistant Secretary for Planning and Evaluation (ASPE) in response to an RFI required by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

ASAM joined the Partnership to Amend 42 CFR Part 2 in expressing appreciation for SAMHSA's issuance of a notice of proposed rulemaking to modify 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records.